Diagnostic and Prognostic Value of Cardiac Magnetic Resonance for Cardiotoxicity Caused by Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

Overview

Journal Rev Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2025 Mar 3

PMID 40026491

Authors

Jialian Li

Yanwei Li

Li Tao

Chuan Zhang

Zhong Zuo

Affiliations

Soon will be listed here.

Abstract

Background: The complex process of cardiac magnetic resonance (CMR) and the uncertainty of each parameter in the diagnosis and prognosis of cardiotoxicity limit its promotion in the cardiac evaluation of patients treated with immune checkpoint inhibitors (ICI).

Methods: A comprehensive search was conducted across PubMed, Web of Science, Embase, China National Knowledge Infrastructure (CNKI), and Cochrane databases for relevant articles published up until September 28, 2024.

Results: After screening, 8 articles were included in this study. The analysis revealed that following ICI treatment, the left ventricular global longitudinal strain (GLS) increased significantly [weighted mean difference (WMD) 2.33; 95% confidence interval (CI) 1.26, 3.41; < 0.01], while the global radial strain (GRS) decreased [WMD -4.73; 95% CI -6.74, -2.71; < 0.01]. Additionally, T1 and T2 values increased [standardized mean difference (SMD) 1.14; 95% CI 0.59, 1.68; < 0.01] and [SMD 1.11; 95% CI 0.64, 1.58; < 0.01], respectively. An elevated T2 was associated with a higher occurrence of major adverse cardiovascular events (MACE), with a hazard ratio of 1.36 (95% CI 1.12, 1.64).

Conclusions: Our findings demonstrate that T1, T2, and GLS increase, while GRS decreases following ICI administration. By consolidating these critical metrics, we propose a streamlined, abbreviated (non-contrast) CMR protocol that can be completed within 15 minutes, thereby facilitating the integration of CMR in cardio-oncology.

The Prospero Registration: CRD42023437238, https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023437238.

References

Itzhaki Ben Zadok O, Levi A, Divakaran S, Nohria A . Severe vs Nonsevere Immune Checkpoint Inhibitor-Induced Myocarditis: Contemporary 1-Year Outcomes. JACC CardioOncol. 2024; 5(6):732-744. PMC: 10774775. DOI: 10.1016/j.jaccao.2023.09.004. View

Galan-Arriola C, Lobo M, Vilchez-Tschischke J, Lopez G, de Molina-Iracheta A, Perez-Martinez C . Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity. J Am Coll Cardiol. 2019; 73(7):779-791. DOI: 10.1016/j.jacc.2018.11.046. View

Eichhorn C, Greulich S, Bucciarelli-Ducci C, Sznitman R, Kwong R, Grani C . Multiparametric Cardiovascular Magnetic Resonance Approach in Diagnosing, Monitoring, and Prognostication of Myocarditis. JACC Cardiovasc Imaging. 2022; 15(7):1325-1338. DOI: 10.1016/j.jcmg.2021.11.017. View

Higgins A, Arbune A, Soufer A, Ragheb E, Kwan J, Lamy J . Left ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity. PLoS One. 2021; 16(2):e0246764. PMC: 7895343. DOI: 10.1371/journal.pone.0246764. View

Arcari L, Tini G, Camastra G, Ciolina F, De Santis D, Russo D . Cardiac Magnetic Resonance Imaging in Immune Check-Point Inhibitor Myocarditis: A Systematic Review. J Imaging. 2022; 8(4). PMC: 9027245. DOI: 10.3390/jimaging8040099. View

Thavendiranathan P, Zhang L, Zafar A, Drobni Z, Mahmood S, Cabral M . Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis. J Am Coll Cardiol. 2021; 77(12):1503-1516. PMC: 8442989. DOI: 10.1016/j.jacc.2021.01.050. View

Mirza J, Sunder S, Karthikeyan B, Kattel S, Pokharel S, Quigley B . Echocardiographic and Cardiac MRI Comparison of Longitudinal Strain and Strain Rate in Cancer Patients Treated with Immune Checkpoint Inhibitors. J Pers Med. 2022; 12(8). PMC: 9410385. DOI: 10.3390/jpm12081332. View

Xu Y, Song Y, Liu X, Shi Y, Liu Y, Qian H . Prediction of major adverse cardiac events is the first critical task in the management of immune checkpoint inhibitor-associated myocarditis. Cancer Commun (Lond). 2022; 42(9):902-905. PMC: 9456696. DOI: 10.1002/cac2.12320. View

Iranzo P, Callejo A, Assaf J, Molina G, Lopez D, Garcia-Illescas D . Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer. Front Med (Lausanne). 2022; 9:875974. PMC: 9189307. DOI: 10.3389/fmed.2022.875974. View

10.

Cadour F, Cautela J, Rapacchi S, Varoquaux A, Habert P, Arnaud F . Cardiac MRI Features and Prognostic Value in Immune Checkpoint Inhibitor-induced Myocarditis. Radiology. 2022; 303(3):512-521. DOI: 10.1148/radiol.211765. View

11.

Mahmood S, Fradley M, Cohen J, Nohria A, Reynolds K, Heinzerling L . Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018; 71(16):1755-1764. PMC: 6196725. DOI: 10.1016/j.jacc.2018.02.037. View

12.

Saunderson C, Plein S, Manisty C . Role of cardiovascular magnetic resonance imaging in cardio-oncology. Eur Heart J Cardiovasc Imaging. 2021; 22(4):383-396. DOI: 10.1093/ehjci/jeaa345. View

13.

Postow M, Callahan M, Wolchok J . Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015; 33(17):1974-82. PMC: 4980573. DOI: 10.1200/JCO.2014.59.4358. View

14.

Waliany S, Lee D, Witteles R, Neal J, Nguyen P, Davis M . Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure. Annu Rev Pharmacol Toxicol. 2020; 61:113-134. DOI: 10.1146/annurev-pharmtox-010919-023451. View

15.

Altaha M, Nolan M, Marwick T, Somerset E, Houbois C, Amir E . Can Quantitative CMR Tissue Characterization Adequately Identify Cardiotoxicity During Chemotherapy?: Impact of Temporal and Observer Variability. JACC Cardiovasc Imaging. 2019; 13(4):951-962. DOI: 10.1016/j.jcmg.2019.10.016. View

16.

Ferreira V, Schulz-Menger J, Holmvang G, Kramer C, Carbone I, Sechtem U . Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. J Am Coll Cardiol. 2018; 72(24):3158-3176. DOI: 10.1016/j.jacc.2018.09.072. View

17.

Lisi C, Catapano F, Rondi P, Figliozzi S, Monaco M, Brilli F . Multimodality imaging in cardio-oncology: the added value of CMR and CCTA. Br J Radiol. 2023; 96(1150):20220999. PMC: 10546447. DOI: 10.1259/bjr.20220999. View

18.

Calvillo-Arguelles O, Thampinathan B, Somerset E, Shalmon T, Amir E, Steve Fan C . Diagnostic and Prognostic Value of Myocardial Work Indices for Identification of Cancer Therapy-Related Cardiotoxicity. JACC Cardiovasc Imaging. 2022; 15(8):1361-1376. DOI: 10.1016/j.jcmg.2022.02.027. View

19.

Quinaglia T, Gongora C, Awadalla M, Hassan M, Zafar A, Drobni Z . Global Circumferential and Radial Strain Among Patients With Immune Checkpoint Inhibitor Myocarditis. JACC Cardiovasc Imaging. 2022; 15(11):1883-1896. PMC: 10334352. DOI: 10.1016/j.jcmg.2022.06.014. View

20.

Michel L, Helfrich I, Hendgen-Cotta U, Mincu R, Korste S, Mrotzek S . Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. Eur Heart J. 2021; 43(4):316-329. DOI: 10.1093/eurheartj/ehab430. View